evaluate the pharmaceuticals company byetta on amgen and glp-1 ADA 2026 confirmed what many of us have been anticipating for years. We're entering a new era of obesity medicine: triple agonists, oral GLP-1s, monthly injections, therapies targeting obesity, diabetes, and Amgen's GLP-1 Drug MariTide Delivers

Instead of asking whether GLP-1 medications work, clinicians are beginning to ask for whom they work best and what alternative pathways should be considered when responses are incomplete. We asked our experts to explain why GLP-1s dont always work for weight loss and what alternatives are available

Its hard to imagine GLP-1 drugs and similar drugs making more of an impact on our collective health than they already have

Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis

Gold nanoparticles (AuNPs), which are biocompatible and immune-modifying, reduce inflammation and promote renal cell regeneration, indicating nephroprotective advantages